Allergan Aesthetics launched its SkinMedica Even & Correct Collection Tuesday morning, featuring a suite of products targeting hyperpigmentation.

The AbbVie subsidiary unveiled its three SkinMedica products, Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads, which even skin tone and reduce the appearance of hyperpigmentation as well as dark spots on the face. 

Advanced Brightening Treatment is a daily serum that aims to prevent visible discoloration while the Dark Spot cream is a targeted, fast-acting spot treatment booster that minimizes the appearance of dark spots. Additionally, the Brightening Treatment Pads are alcohol-free pads that exfoliate and reduce the appearance of dullness and uneven tone.  

The company noted that these SkinMedica offerings are “hydroquinone-free, well tolerated, and effective on all skin types” as well as for multiple ethnicities. Allergan Aesthetics added that the results of these treatments can be complemented through a DiamondGlow treatment with Even & Correct Advanced Brightening Pro-Infusion Serum.

“Hyperpigmentation is the second-highest professional-grade skincare concern seen in-office1 with demand for effective treatment continuing to rise,” said Carrie Strom, president of global of Allergan Aesthetics and SVP of AbbVie, in a statement. “With a formulation backed by science, our R&D team has developed an innovative collection to meet patients where they are in their hyperpigmentation journey. SkinMedica continues to be a category leader innovating for all patient skin types.”

SkinMedica represents yet another endeavor by Allergan Aesthetics to expand its interests in the skincare field and empower a variety of patients, too.

In the fall, Allergan Aesthetics teamed with Skinbetter Science for The DREAM Initiative (Driving Racial Equity in Aesthetic Medicine) to address systemic racism in the industry and make aesthetic products more inclusive for an increasingly diverse consumer base. 

Before that, the company revealed the 25 cast members chosen for its See Yourself campaign supporting Botox. The effort featured stories detailing patients’ motivations for receiving the non-surgical cosmetic procedure. 

Allergan Aesthetics launched the SkinMedica Even & Correct Collection three weeks before AbbVie is scheduled to release its Q4 2022 earnings report. 

In its most recent earnings report, aesthetics remained a revenue generator for AbbVie, with the portfolio growing 4% to just over $1.3 billion as Botox generated $637 million in net revenues.